Edwards Lifesciences Corporation (EW) has been experiencing a series of stock changes, with firms and investors alike altering their holdings in the company. Notably, Texas Permanent School Fund Corp, Glenview Trust co, Edgestream Partners L.P., and Nebula Research & Development LLC have sold off their shares. Contrastingly, Orser Capital Management LLC, Hudson Bay Capital Management LP, and Squarepoint Ops LLC increased their EW positions, expressing their confidence in the company. Despite Canaccord Genuity lowering EW's price target, JP Morgan elevated their rating to overweight, indicating mixed market sentiments.
On the performance front, EW stocks haven't seen much fluctuation, but the company's robust sales growth and revised 2025-2026 outlook hint towards a positive growth trajectory. Amidst the stock investment game, Edwards Lifesciences Corporation also announced their plans to present at the 44th Annual J.P. Morgan Healthcare Conference. The firm’s reaffirmation of its growth strategy also indicates that EW remains committed to sustainable and differentiated expansion in the healthcare sector. Finally, despite some suggestions of overvaluation, the company’s solid financial health and consistent growth in the medical device market underpin a key role for the stock in investor portfolios.
Edwards Lifesciences Corp EW News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 20 Dec 2025 10:29:04 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -3
